Commercial Launch Initiated for Neonorm Dog, Jaguar Health's Non-Prescription Product for Support of Normal Stool Consistency and GI Fluid Balance in Dogs
Rhea-AI Summary
Jaguar Health (NASDAQ:JAGX) announced the initiation of the commercial launch of Neonorm Dog, a non-prescription, plant-based product designed to support normal stool consistency and gastrointestinal (GI) fluid balance in dogs. The product extends Jaguar's existing Neonorm franchise, which currently includes Neonorm Foal and Neonorm Calf.
Neonorm Dog uses a standardized botanical extract from the sustainably harvested Croton lechleri tree, acting locally in the gut, and is positioned as a science-based option for managing episodes of loose stools in dogs. Jaguar expects Neonorm Dog to be available shortly through select online and animal health retail channels, including Amazon and Chewy, aiming to broaden the company’s commercial footprint in the companion animal market and increase awareness of the Neonorm brand among pet owners, veterinarians, and animal health retailers.
Positive
- None.
Negative
- None.
News Explained
Neonorm Dog’s stated scope is limited to supporting normal stool consistency and gastrointestinal fluid balance; Jaguar says it is not intended to diagnose, treat, cure, or prevent disease, or replace veterinary care.
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Aug 19 | Q2 earnings | Negative | -5.5% | Revenue declined 59% year over year while net loss attributable to stockholders increased. |
| Aug 18 | Investor webcast | Neutral | +11.1% | Company scheduled a webcast to review Q2 financials and provide corporate updates. |
| Aug 05 | Holdback payment | Positive | +5.5% | Jaguar satisfied conditions to receive a non-dilutive $2 million payment. |
| Jul 28 | Market research | Positive | -3.5% | Surveys indicated favorable veterinarian and dog-owner interest in Neonorm Dog. |
| Jul 22 | Compassionate use | Positive | +5.6% | Napo provided crofelemer to an additional infant with intestinal failure. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
JAGX's recent news reactions were mixed, with three aligned moves and two divergences across positive and negative announcements.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Neonorm® Dog extends Jaguar's existing Neonorm product franchise beyond foals and calves to provide dog owners with access to a plant-based product designed to support normal stool consistency and GI fluid balance in dogs
Jaguar expects to make Neonorm Dog available through both Amazon and Chewy soon
SAN FRANCISCO, CA / ACCESS Newswire / August 26, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced the initiation of the commercial launch of Neonorm Dog, a new extension of Jaguar's Neonorm franchise for companion and production animals. Neonorm Dog is designed to provide dog owners with access to a plant-based, non-prescription product intended to support normal stool consistency and GI fluid balance in dogs.
"Neonorm Dog brings Jaguar's longstanding expertise in plant-based gastrointestinal health to the companion animal market. We are excited to offer dog owners a differentiated approach to digestive support that builds on the science and experience behind the Neonorm brand, while providing a product designed specifically for the needs of dogs," said Ian Wendt, Jaguar's Chief Business Officer. "We believe Neonorm Dog addresses an important and very common need for dog owners who want a convenient option to help manage episodes of loose stools. Our goal with this launch is to bring a differentiated, science-based product to pet owners through channels that make it easy to find, purchase and use when they need it."
The Neonorm franchise currently includes Neonorm Foal and Neonorm Calf, plant-based products developed to support proper hydration and bowel health in pre-weaned foals and calves. Neonorm products contain a standardized botanical extract derived from the sustainably harvested Croton lechleri tree, which acts locally in the gut.
"For dog owners, an episode of loose stools can quickly become a source of concern, and they want something they can reach for with confidence. With Neonorm Dog, we saw an opportunity to combine Jaguar's gastrointestinal expertise with an easy-to-use product that can become a trusted part of the at-home toolkit for managing these common digestive episodes," Wendt added.
"We are very excited about the launch of this important addition to our Neonorm product line. Neonorm Dog is designed as a science-backed replacement for uncertain home remedies for digestive support that owners can keep on hand before symptoms start," said Lisa Conte, Jaguar's founder, president and CEO.
Jaguar expects Neonorm Dog to be available through select online and animal health retail channels shortly, including Amazon and Chewy. The launch of Neonorm Dog is intended to broaden Jaguar's commercial footprint in the companion animal market and extend consumer awareness of the Neonorm brand. Dogs represent one of the largest companion animal populations in the United States and Europe, and Jaguar believes Neonorm Dog may create an opportunity to reach pet owners, veterinarians, and animal health retailers seeking non-antibiotic, plant-based options to support digestive health.
About Neonorm
Neonorm is Jaguar's non-prescription animal-health franchise of plant-based products developed to support digestive health, hydration, and normal stool consistency in animals. Existing Neonorm products include Neonorm Foal and Neonorm Calf. Neonorm Dog is not intended to diagnose, treat, cure, or prevent any disease and is not intended as a substitute for veterinary care.
About the Jaguar Health Family of Companies
Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress. Jaguar family companies Napo Pharmaceuticals, Inc. (Napo) and Napo Therapeutics S.p.A. focus on the development and commercialization of novel crofelemer powder for oral solution for the treatment of rare and orphan gastrointestinal disorders with intestinal failure, including microvillus inclusion disease and short bowel syndrome.
For more information about:
Jaguar Health, visit https://jaguar.health
Napo Pharmaceuticals, visit napopharma.com
Napo Therapeutics, visit napotherapeutics.com
Forward-Looking Statements
Certain statements in this press release constitute "forward-looking statements." These include statements related to Jaguar's launch of Neonorm Dog, and Jaguar's expectation that Neonorm Dog will be available through select online and animal health retail channels, including Amazon and Chewy. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to several risks, uncertainties, and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
Contact:
Jaguar-JAGX
SOURCE: Jaguar Health, Inc.
View the original press release on ACCESS Newswire